We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
-8.18%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.06B
AUM Growth
-$181M
Cap. Flow
-$8.21M
Cap. Flow %
-0.78%
Top 10 Hldgs %
88.26%
Holding
30
New
–
Increased
4
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$4.28M
2
SAGE
Sage Therapeutics
SAGE
+$4.22M
3
GOSS icon
Gossamer Bio
GOSS
+$3.53M
4
NVCR icon
NovoCure
NVCR
+$2.37M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$11.9M
2
ALGN icon
Align Technology
ALGN
+$6.53M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$2.65M
4
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$1.3M
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$251K

Sector Composition

Rank Sector Weight
1 Healthcare 98.08%
2 Financials 1.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
1
BioMarin Pharmaceuticals
BMRN
$13.5B
$162M 15.33%
1,831,035
– –
INSM icon
2
Insmed
INSM
$29B
$149M 14.07%
5,889,491
– –
UTHR icon
3
United Therapeutics
UTHR
$22.1B
$130M 12.31%
575,907
-51,607
-8% -$11.9M
FOLD
4
DELISTED
Amicus Therapeutics
FOLD
$128M 12.11%
10,524,022
– –
BIIB icon
5
Biogen
BIIB
$30.1B
$98M 9.27%
381,282
– –
PRTA icon
6
Prothena Corp
PRTA
$473M
$80M 7.57%
1,657,458
– –
RVNC
7
DELISTED
Revance Therapeutics, Inc.
RVNC
$60M 5.67%
5,228,609
– –
STAA icon
8
STAAR Surgical
STAA
$1.24B
$55.2M 5.23%
1,374,822
– –
ACAD icon
9
Acadia Pharmaceuticals
ACAD
$5.07B
$50.1M 4.74%
2,405,793
– –
SAGE
10
DELISTED
Sage Therapeutics
SAGE
$20.7M 1.96%
1,005,776
+146,259
+17% +$4.22M
EHTH icon
11
eHealth
EHTH
$39.1M
$20.3M 1.92%
2,739,379
– –
ALGN icon
12
Align Technology
ALGN
$12.3B
$17M 1.61%
55,705
-18,900
-25% -$6.53M
ALKS icon
13
Alkermes
ALKS
$8.26B
$16.9M 1.6%
603,400
– –
SRPT icon
14
Sarepta Therapeutics
SRPT
$1.92B
$11.4M 1.08%
94,030
– –
NVCR icon
15
NovoCure
NVCR
$2.06B
$10.7M 1.01%
660,275
+82,157
+14% +$2.37M
ANAB icon
16
AnaptysBio
ANAB
$1.71B
$7.74M 0.73%
431,224
– –
KPTI icon
17
Karyopharm Therapeutics
KPTI
$47.6M
$7.61M 0.72%
378,392
– –
NVRO
18
DELISTED
NEVRO CORP.
NVRO
$7.43M 0.7%
386,832
+200,573
+108% +$4.28M
SNDX icon
19
Syndax Pharmaceuticals
SNDX
$1.81B
$6.86M 0.65%
472,600
-140,000
-23% -$2.65M
GOSS icon
20
Gossamer Bio
GOSS
$88.9M
$5.44M 0.51%
6,530,288
+3,065,136
+88% +$3.53M
CYTK icon
21
Cytokinetics
CYTK
$10.6B
$3.29M 0.31%
111,717
– –
RLMD icon
22
Relmada Therapeutics
RLMD
$477M
$2.2M 0.21%
732,400
– –
MIRM icon
23
Mirum Pharmaceuticals
MIRM
$5.99B
$2.04M 0.19%
64,700
– –
TVTX icon
24
Travere Therapeutics
TVTX
$5.68B
$1.48M 0.14%
166,069
– –
VNDA icon
25
Vanda Pharmaceuticals
VNDA
$298M
$1.21M 0.11%
278,985
-45,088
-14% -$251K
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $649M AUM
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
RK
Rather & Kittrell Knoxville, Tennessee $648M AUM 14.68% 1-Year Est. Return

Palo Alto Investors's Q3 2023 Portfolio in Review

As of Q3 2023, Palo Alto Investors held 30 positions worth $1.06B, down 15% from $1.24B the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Trading was light in Q3 2023: portfolio turnover was 3.3%. Palo Alto Investors opened no new positions and exited 1, leaving the 30-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Financials.

  • Palo Alto Investors added most to NEVRO CORP. in Q3 2023, an estimated $4.28M increase.
  • Palo Alto Investors's biggest Q3 2023 reduction was United Therapeutics, cutting an estimated $11.9M.
  • Palo Alto Investors fully exited Gritstone bio, Inc. Common Stock in Q3 2023, selling an estimated $1.3M.
  • Palo Alto Investors's ten largest holdings make up 88% of its $1.06B portfolio in Q3 2023.
  • Palo Alto Investors opened 0 new positions and closed 1 in Q3 2023.
  • Palo Alto Investors's portfolio value fell 15% quarter-over-quarter to $1.06B.

Based on Palo Alto Investors's 13F filing for Q3 2023, filed 14 Nov 2023.